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ABSTRACT 
Background: Umbilical-derived mesenchymal stromal cells (USC) have shown promise in the protection of 
ischemic organs.   We hypothesized that USCs would improve mesenteric perfusion, preserve intestinal 
histological architecture, and limit inflammation by nitric oxide dependent mechanisms following intestinal 
ischemia/reperfusion injury (IR).  
Methods: Adult wild type C57BL/6J (WT) and endothelial nitric oxide synthase knock out (eNOS KO) mice 
were used: 1) WT IR+Vehicle, 2) WT IR+USC, 3) eNOS KO IR+Vehicle and 4) eNOS KO IR+USC. Mice were 
anesthetized and a midline laparotomy was performed. The superior mesenteric artery was clamped with a 
non-occluding clamp for 60-minutes. Following IR, mice were treated with an injection of 250µL phosphate 
buffered saline (PBS) or 2x106 USCs suspended in 250µL PBS. Mesenteric perfusion images were acquired 
using laser Doppler imaging.  Perfusion was analyzed as a percentage of baseline. At 24 hours, mice were 
euthanized and intestines were harvested. Intestines were evaluated for injury and data were analyzed using 
the Mann-Whitney or Kruskal-Wallis tests. 
Results: Intestinal mesenteric perfusion was significantly improved in WT mice treated with USC therapy 
compared to eNOS KOs.  Intestinal histological architecture was preserved with USC therapy in WT mice. 
However, in eNOS KO mice, this benefit was abolished. Lastly, the presence of several cytokines and growth 
factors were significantly improved in WT mice compared to eNOS KO mice treated with USCs. 
Conclusion: The benefits of USC-mediated therapy following intestinal IR injury likely occur via nitric oxide 
dependent pathways. Further studies are required to define the molecular mechanisms by which USCs 
activate endothelial nitric oxide synthase to bring about their protective effects.   
 
INTRODUCTION 
Acute mesenteric ischemia (AMI) continues to be a devastating intra-abdominal emergency with mortality 
as high as 60-80% and accounts for about 0.1% of all hospital admissions (1, 2). It is caused by either 1) a 
sudden acute arterial occlusion, 2) a venous occlusion or 3) a sudden drop in circulating pressure. During 
hypoperfusion, this insufficient blood flow within the mesenteric circulation is unable to meet intestinal 
metabolic demands, and often, this leads to mesenteric infarction and intestinal necrosis. Patients who remain 
untreated can quickly decompensate and progress to shock, multi-system organ failure and death (3). The 
most critical factor that continues to impact outcomes in patients is the time to diagnosis and intervention.  
If patients survive these ischemic episodes, they are often faced with prolonged hospitalization and long 
term parenteral nutrition needs (4). Additionally, reported overall survival at one, three and five years following 
surgery for AMI has been found to be 26%, 23%, and 21% respectively (5). Early diagnosis and aggressive 
therapy may significantly reduce the morbidity and mortality of this life-threatening disease. While clinical 
studies emphasize diagnostic and therapeutic algorithms to expedite treatment for the diagnosis of AMI, the 
disease prognosis remains dismal. To that end, noteworthy advancements in the medical treatment of 
intestinal ischemia within the last decade have been sparse and a novel therapeutic option is of the utmost 
importance.  
Recent animal studies have demonstrated the ability to reverse ischemic injury and promote recovery of 
intestinal tissue with use of mesenchymal stromal cells (MSCs) following ischemia-reperfusion (IR) injury (3, 6-
8). Umbilical-derived mesenchymal stromal cells (USCs) are pluripotent, immunomodulatory, and reduce 
inflammation (9). They are easily isolated from neonates and obtained from discarded tissue. Of all the types of 
mesenchymal stromal cells (adipose-derived, bone marrow-derived, etc.), they are the least senescent and 
have the lowest expression of MHC II, which may enhance cell survival during transplant (9).  
Mesenchymal stromal cells originally were thought to allow for tissue repair through transdifferentiation or 
cell fusion. However, several studies have now demonstrated that functional benefits observed with use of 
MSCs following injury are most likely related to the secretion of bioactive mediators acting in a paracrine 
fashion on the affected tissue (10). Many of these factors include epidermal growth factor, insulin-like growth 
factor, transforming growth factor beta1, hepatocyte growth factor,interleukin6, interleukin10 and vascular 
endothelial growth factor (11, 12). While all of these paracrine mediators have been found to contribute to 
improved tissue repair and angiogenesis following ischemic injury, it is still unclear how they promote improved 
mesenteric perfusion following injury.  
In this regard, nitric oxide (NO) could be an important downstream contributor to USC mediated 
improvements in mesenteric perfusion.  Nitric oxide is known to be a potent vasodilator through relaxation of 
vascular smooth muscle cells. In the setting of intestinal IR injury, studies have found that endogenous nitric 
oxide production increases, most likely to promote improved perfusion to ischemic organs (13, 14).  Within the 
microvascular endothelial bed, nitric oxide is produced by endothelial nitric oxide synthase (eNOS).  Therefore, 
it is possible that USCs may work through endothelial nitric oxide synthase pathways to bring about their 
protective effects. We hypothesized that: 1) USCs would improve mesenteric perfusion, preserve intestinal 
histological architecture, and limit intestinal inflammation following intestinal IR injury and 2) the benefits of 
USC therapy would be mediated through endothelial nitric oxide synthase-dependent pathways. 
MATERIALS AND METHODS 
Animals 
Wild-type adult male mice (C57BL/6J, 8-12 weeks; Jackson Laboratory, Bar Harbor, ME) and 
endothelial nitric oxide synthase knock out (eNOS KO) mice on a C57BL/6J background (B6.129P2-
Nos3tm1Unc/J, 8-12 weeks; Jackson Laboratory, Bar Harbor ME) were used for all animal experimentation. 
Animals underwent at least 48 hours of acclimation to the new environment prior to experimentation. Twelve 
hour light/dark cycle housing and normal chow and water were provided to all animals. All experimental 
protocols were approved by the Institutional Animal Care and Use Committee at Indiana University.   
Cell Culture 
The human umbilical-derived mesenchymal stromal cells used for experimentation were purchased 
from ATCC (Manassas, VA). Cells were positive for CD29, CD44, CD73, CD90, CD105, and CD166 and 
negative for CD14, CD31, CD34 and CD45 (15). Cells were cultured in 225 cm2 polystyrene culture flasks in 
Mesenchymal Stem Cell Basal medium with Mesenchymal Stem Cell Growth Kit – Low Serum (ATCC, 
Manassas, VA) at 37˚C in a humidified atmosphere of 5% CO2 in air. Once cells reached 90% confluency they 
were lifted from the flask with TrypLE Express (Life Technologies) and passaged to expand primary cultures or 
used in experimentation.  USCs were used between passages 4-9. A fluorescent automated cell counter was 
used to count cells (Luna™ Automated Cell Counter, Logos Biosystems Inc., Annandale, VA).  
Ischemia/Reperfusion Model 
For all experimental groups, mice were anesthetized using 3% isoflurane followed by maintenance at 
1.5% isoflurane in oxygen. Temperature homeostasis was maintained intra-operatively through the use of an 
animal heating pad. All murine abdomens were prepped using hair removal lotion followed by sterile 
preparation with 70% ethanol and betadine. Prior to surgery all animals were subcutaneously injected with 
one milliliter of 0.9% normal saline solution to account for intra-operative fluid loss. Peri-operative analgesia 
included 1 mg/kg buprenorphine and 5mg/kg carprofen administered by subcutaneous injection.  
  Using a previously described sterile technique, a midline laparotomy was performed and the 
intestines were eviscerated. Using an atraumatic microvascular clamp, the superior mesenteric artery was 
clamped to cause intestinal ischemia. The intestines were then returned to the abdominal cavity and the 
abdomen was closed temporarily for a total of 60 minutes to prevent evaporative losses. Following the 
ischemic period, the abdominal cavity was reopened and the atraumatic clamp was removed. Animals then 
received an intraperitoneal injection of 250 µL PBS as our vehicle control or 2x106 umbilical-derived MSCs 
re-suspended in 250 µL of PBS. In a two-layer fashion, the abdominal fascia and skin were then closed with 
suture. Following surgery all animals were allowed to recover and awaken on a heating pad. Once they had 
fully recovered, they were returned to our laboratory animal resource center (3).  
Perfusion Analysis  
Animals were assigned to the perfusion protocol (N=10 per group) as follows: 1) WT IR + vehicle, 2) 
WT IR + USCs, 3) eNOS KO IR + vehicle, and 4) eNOS KO IR + USCs. Using a Laser Doppler Perfusion 
Imager (LDI; Moor Instruments, Wilmington, DE), mesenteric and intestinal perfusion was analyzed. 
Acquisition of images occurred at baseline, at initial clamping of the superior mesenteric artery and at 24 
hours following reperfusion. Intestines were eviscerated and oriented in a standard fashion beneath the laser 
in order to eliminate bias.  Using these images, a region of analysis was created around the eviscerated 
intestines to obtain a flux mean perfusion within this region.  At each of the three time points a total of three 
images were acquired and averaged. The perfusion was then expressed as a percentage of baseline. Once 
perfusion images were obtained, animals were euthanized through overdose of isoflurane and cervical 
dislocation. Intestines were then harvested for further analysis (3).  
Histological Injury Score 
In all experimental groups, intestinal tissues were harvested following euthanasia (N=10 per group). 
The terminal ileums were fixed using 4% paraformaldehyde with subsequent dehydration in 70% ethanol. 
Intestines were paraffin-embedded, sectioned, and subsequently stained with hematoxylin and eosin. A 
histological scoring method of intestinal damage was used as previously described: 0, no damage; 1, 
subepithelial space at the villous tip; 2, loss of mucosal lining at the villous tip; 3, loss of less than half of the 
villous structure; 4, loss of more than half of the villous structure; and 5, transmural necrosis (16, 17) . All 
histological sections were evaluated by two blinded authors (ARJ, NAD) and scores were averaged.  
Intestinal Cytokine Analysis 
Following euthanasia, all mouse intestinal tissue was harvested and snap frozen in liquid nitrogen and 
stored at -80ºC for later use. For protein analysis, intestines were thawed and homogenized in RIPA buffer 
(Sigma, St. Louis, MO) with phosphatase and protease inhibitors (1:100 dilution, Sigma, St. Louis, MO). A 
Bullet Blender tissue homogenizer (Next Advance, Averill Park, NY) was used for tissue homogenization. After 
homogenization, samples were centrifuged at 12,000 rpm to pellet extraneous tissue. Supernatants were then 
collected in fresh Eppendorf tubes and total protein concentration was quantified with the Bradford Assay using 
a spectrophotometer (VersaMax microplate reader; Molecular Devices, Sunnyvale, CA).  
For measurement of murine intestinal inflammatory cytokine and growth factor production, a Bio-Plex 
200 multiplex beaded assay system (Bio-Rad, Hercules, CA) was used. The multiplex assay was ran a total of 
three times (N=13-25 per group based on plate restrictions). Assays were performed at 1:25 dilution according 
to the manufacturer’s instructions. Assayed cytokines and growth factors included interleukin 6 (IL-6), 
interleukin 9 (IL-9), interleukin 10 (IL-10), C-X-C ligand 10 (IP-10), granulocyte-colony stimulating factor (G-
CSF), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and angiopoietin 2 (ANPT-
2). In order to account for variations in individual plates and assays, cytokines were normalized to their 
respective vehicle controls for both WT and eNOS KO intestinal samples.  
Statistical Analysis  
GraphPad Prism 7 (GraphPad Software, La Jolla, CA) was used for all statistical analysis and figures. 
For power analysis we used a confidence level of 95% and a power of 80%. We estimated there would be a 
50% difference between treatment and vehicle groups.  Therefore, based on our analysis, a minimum of 8 
animals would be needed per group. For the study we used a total of 10 animal in each group. To account for 
any outliers, prior to data analysis, raw data was assessed by robust regression and outlier removal (ROUT 
method). Groups were compared using Mann-Whitney and Kruskal-Wallis tests for nonparametric variables.  
P-values less than 0.05 were considered statistically significant.  
 
RESULTS 
Mesenteric Perfusion is improved with USC Therapy following IR through eNOS Dependent Pathways 
Intestinal mesenteric perfusion was compared at 24 hours following IR injury in all treatment groups 
(Figure 1A).  One animal in each group was removed after performing analysis of outliers (ROUT method).  
This left nine animals per group for perfusion analysis.  Treatment with USCs significantly improved mesenteric 
perfusion in the wild-type animals compared to vehicle treatment alone (WT Vehicle=32.6±7.7, WT 
USCs=68.2±5.0, p=0.02). While there was significant improvement in perfusion in WT animals with USC 
therapy, this was not observed in the eNOS KO animals (eNOS KO Vehicle=32.7±6.1, eNOS KO 
USCs=37.9±11.8, p=>0.9; Figure 1B).  
Histological Architecture is preserved with USC Therapy following IR through eNOS Dependent Pathways 
Intestinal architecture was compared at 24 hours following IR injury (N=10/group, Figure 2A). In wild-
type animals, USC therapy significantly improved the preservation of intestinal architecture compared vehicle 
alone (WT Vehicle=3.4±0.3, WT USCs=0.6±0.2, p=<0.01). Additionally, while there was preservation of the 
intestinal architecture in WT animals following USC therapy, this was not observed in eNOS KO animals 
(eNOS KO Vehicle=4.0±0.2, eNOS KO USCs=3.0±0.2, p=0.1; Figure 2B).  
USCs Increase Cytokine Production following IR Injury through eNOS Dependent Pathways 
Intestinal inflammatory cytokine production following IR injury was significantly impacted by USC 
therapy and these effects were found to be mediated through eNOS dependent pathways (Figures 3). IL-9 
production after USC therapy was significantly decreased in eNOS KO animals compared to WT animals (WT 
= 1.5±0.2, eNOS KO = 0.9±0.1; p=<0.01). The production of IL-10, a critical anti-inflammatory cytokine, was 
significantly decreased in eNOS KO animals compared to WT animals after USC therapy (WT = 1.6±0.2, 
eNOS KO = 0.6±0.1; p=<0.01). Lastly, the production of IP-10, a known cellular chemoattractant, was 
significantly decreased with USC therapy in eNOS KO animals compared to WT (WT = 1.0±0.1, eNOS KO = 
0.4±0.0; p=<0.01). IL-6 levels following USC therapy was not significantly different between WT and eNOS KO 
animals (WT = 0.7±0.3, eNOS KO = 0.2±0.1; p=0.6). 
USCs Promote Growth Factor Production following IR Injury through eNOS Dependent Pathways 
 Intestinal production of multiple growth factors following USC therapy was also found to be mediated 
through eNOS dependent pathways (Figure 4). G-CSF was significantly decreased with USC therapy in eNOS 
KO animals (WT = 0.4±0.1, eNOS KO = 0.1±0.0; p=0.02), while HGF was significantly increased in eNOS KO 
animals compared to WT animals (WT = 0.4±0.1, eNOS KO = 0.6±0.1; p=0.02). In addition, intestinal VEGF 
and ANGPT-2 levels were significantly decreased in eNOS KO animals compared to WT (VEGF: WT = 
1.2±0.1, eNOS KO = 0.7±0.1; p=<0.01, ANGPT-2: WT = 1.1±0.2, eNOS KO = 0.5±0.1; p=<0.01).  
DISCUSSION 
 Acute mesenteric ischemia continues to be a devastating intra-abdominal emergency with high 
morbidity and mortality and limited ability to salvage ischemic bowel. While current management focuses on 
resuscitation, embolectomy, revascularization and resection; there is no available treatment modality aimed at 
recovery of the already ischemic intestine. Therefore, novel therapies are being explored. To this end, we have 
observed that umbilical-derived mesenchymal stromal cell therapy for intestinal ischemia may allow for 
recovery of the damaged tissues and allow for intestinal preservation. Additionally, these protective effects may 
be mediated, in part, by endothelial nitric oxide synthase dependent pathways.  
This study demonstrated that intraperitoneal USC therapy following intestinal IR injury improved 
mesenteric perfusion, prevented intestinal mucosal damage, and increased the production of certain 
inflammatory mediators associated with injury. Our findings corroborate similar findings in other studies of MSC 
therapy for intestinal ischemia that observed reduced intestinal barrier disruption (3, 18), improved mesenteric 
perfusion (3, 6), suppression of pro-inflammatory cytokine production, and increased expression of anti-
inflammatory cytokines (3, 6, 8).  
While all of these studies have demonstrated intestinal recovery after IR with use of MSCs, there have 
been limited studies specifically examining the role of nitric oxide as a downstream mediator in relation to 
intestinal protection by USCs. Herein, we found that improvements in mesenteric perfusion and preservation of 
intestinal architecture were lost when eNOS was genetically ablated. Our findings suggest that nitric oxide 
production plays a key role in the downstream benefits of MSC therapy. Similarly, in a swine model of 
myocardial IR, Song et al. demonstrated that the benefits of MSC therapy were in part mediated by activation 
of eNOS, and observed that benefits of MSCs were abated with use of a NOS inhibitor (19). Additionally, other 
studies have confirmed that nitric oxide concentrations increase with ischemia and play a protective role in 
limiting tissue damage (13, 14).   
Nitric oxide is a gasotransmitter known to play a key role in angiogenesis and vasorelaxation. Within 
the endothelium, eNOS uses L-arginine as a precursor to form nitric oxide (20). NO can then diffuse into 
neighboring smooth muscle cells to activate soluble guanylate cyclase which then converts guanosine 
triphosphate into cyclic guanosine monophosphate (cGMP).  cGMP then activates Protein Kinase G which has 
a number of downstream targets that work to cause smooth muscle cell relaxation (20).  
By using competitive eNOS inhibitors such as NG-monomethyl-L-arginine (LNMMA) and NG-nitro-L-
arginine-methyl ester (L-NAME), previous studies have highlighted the importance of eNOS in the control of 
vasodilation and angiogenesis (21).  In a model of hind-limb ischemia, eNOS deficient mice were found to not 
only develop a severe form of critical limb ischemia, but also to exhibit impaired wound healing and defective 
angiogenesis (22, 23).The role that eNOS plays on angiogenesis is likely through downstream mediators of 
VEGF, as previous work has demonstrated impaired angiogenesis in eNOS KO mice following hind limb 
ischemia even when VEGF was administered exogenously (23).  Other studies have also found that the 
production of VEGF enhances the expression of eNOS in endothelial cells possibly through post-transcriptional 
effects on eNOS mRNA stability (24). This up-regulation in expression may be important in the process of 
VEGF-induced angiogenesis.  In this current study, we observed a significant decrease in the intestinal 
angiogenic factors VEGF and ANGPT-2 following USC therapy in eNOS KO animals compared to wildtypes. 
These findings may suggest a critical relationship between stromal cell therapy, eNOS production, and 
angiogenesis in that USCs may not be able to effectively facilitate angiogenesis in the absence of eNOS. 
Multiple other cytokines were also measured following intestinal IR injury. We observed a significant 
decrease in the production of IL-9, IL-10 and IP-10 in eNOS KO animals compared to WT animals following 
USC therapy.  IL-9 is known to regulate activated T-cell proliferation and immunoglobulin production (25). 
Additionally, it is known to promote mast cell proliferation and cytokine secretion. While it was significantly 
increased following USC therapy in the WT group, this was not observed in the eNOS KO animals suggesting 
that the role of IL-9 in inflammatory disease may in part be regulated by eNOS dependent mechanisms.  IL-10, 
a known anti-inflammatory cytokine was similarly increased with USC therapy in WT animals compared to 
eNOS KO animals.  This anti-inflammatory cytokine has been found to be upregulated in other studies of MSC 
therapy following ischemic injury (26) and likely plays a protective role by limiting intestinal inflammation (27). 
Similarly, significant elevations in IP-10, a known chemoattractant, were observed in WT animals compared to 
eNOS KO animals following therapy. The significant decrease in these cytokines following USC therapy in 
eNOS KO mice suggests a dependency on eNOS for their production.  
Lastly, HGF production was elevated following USC therapy in eNOS KO animals compared to 
wildtypes. HGF is known to stimulate chemotactic migration of MSCs and it is thought that it may play an 
important role in MSC recruitment to sites of tissue regeneration (28). Consequently, eNOS may play a role in 
suppressing this pathway under normal situations, possibly as a way to provide a check and balance pathway 
in tissue regeneration. Overall, the differences in production of growth factors and cytokines between wildtype 
and eNOS KO reinforce the idea that multiple complex pathways are used by MSCs to enhance recovery and 
allow for tissue repair following injury.  
LIMITATIONS 
This study has several limitations that may affect the impact of the results. First, for this study, human 
umbilical-derived mesenchymal stromal cells were utilized as a preclinical assessment in a mouse model of 
intestinal IR injury. In immunocompetent hosts, cross species transplantation is usually not possible and these 
beneficial effects are usually not observed. However, it is known that MSCs have the unique ability to suppress 
T-lymphocyte proliferation and thus allow for xenotransplantation (7, 29).   
Additionally, the superior mesenteric artery occlusion model of intestinal IR injury is not the most 
representative of what is commonly seen in the clinical setting. While complete small bowel ischemia is 
certainly devastating and quite possible through an SMA thrombus or embolus, intestinal ischemia more 
commonly only affects a portion of the small bowel.  Nevertheless, this model allows for the most severe form 
of intestinal injury to be used for examination of the effectiveness of various therapeutic strategies.   
Lastly, despite normalizing for total protein concentration in intestinal tissue a wide variety of cytokine 
levels were observed between samples. While we used similar amounts of intestine from similar areas of the 
gastrointestinal tract, it is possible that there could be certain segments of ischemic bowel that have higher or 
lower levels of cytokine production and are therefore not completely equivalent in this investigation.  
CONCLUSION 
In conclusion, direct intraperitoneal application of USCs in the setting of acute mesenteric ischemia is 
an innovative approach to a very devastating and morbid disease. Herein, we demonstrated that USCs 
improve mesenteric perfusion, preserve intestinal histological architecture and moderate intestinal 
inflammatory cytokine and chemokine production. Additionally, these beneficial effects appear to be mediated 
through endothelial nitric oxide synthase pathways. While these benefits have been observed and it has 
become clear that eNOS plays a significant role in tissue recovery following injury, we still do not know all of 
the downstream effects of these pluripotent immunomodulatory cells. Therefore, additional studies must be 
done to further investigate and delineate these mechanisms prior to clinical application.   
 
FIGURE LEGENDS 
Figure 1. Mesenteric perfusion following intestinal IR and USC therapy. A. Representative images from Laser 
Doppler Imager at 1) baseline, 2) SMA occlusion, and 3) 24 hours after ischemic injury in each respective 
treatment group (WT IR + Vehicle, WT IR + USC, eNOS KO + Vehicle and eNOS KO + USC). B. USC therapy 
significantly improved mesenteric perfusion in WT animals compared to eNOS KO mice at 24 hours 
reperfusion (*p=<0.05 vs. WT IR + USCs). 
 
Figure 2. Histological examination of small intestine following intestinal IR injury and USC therapy. A. 
Representative histology slides of each treatment group ((WT IR + Vehicle, WT IR + USC, eNOS KO + Vehicle 
and eNOS KO + USC; hematoxylin and eosin stain x20). B. Histological scoring of intestinal specimens: 0, no 
damage; 1, sub-epithelial space at the villous tip; 2, loss of mucosal lining of the villous tip; 3, loss of less than 
half of the villous structure; 4, loss of more than half of the villous structure; and 5, transmural necrosis. USC 
therapy significantly improved histological mucosal injury grade in WT animals compared to eNOS KO mice at 
24 hours reperfusion (*p=<0.05 vs. WT IR + USCs). 
 
Figure 3. Intestinal cytokine analysis following IR injury and USC therapy at 24 hours reperfusion. All cytokine 
production is presented as a ratio of USC therapy/PBS Vehicle therapy in both the WT and eNOS KO animals. 
Following intestinal IR injury mouse intestines were homogenized and assessed for murine expression of IL-6, 
IL-9, IL-10, and IP-10 (*p=<0.05 vs. WT).  
 
Figure 4.  Intestinal growth factor production following IR injury and USC therapy at 24 hours reperfusion. All 
growth factor production is presented as a ratio of USC therapy/PBS Vehicle therapy in both WT and eNOS 
KO animal. Following intestinal IR injury mouse intestines were homogenized and assessed for murine 
expression of HGF, G-CSF, VEGF, and ANPT-2 (*p=<0.05 vs. WT). 
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